Evidence map›Paper›PMID 32902058›Full record

ArticleJournal of the peripheral nervous system : JPNS2020

Oxaliplatin- and docetaxel-induced polyneuropathy: clinical and neurophysiological characteristics.

Kristine Bennedsgaard, Lise Ventzel, Niels T Andersen, Andreas C Themistocleous, David L Bennett, Troels S Jensen, Hatice Tankisi, Nanna B Finnerup

Open access · hybridAbstract read
In one paragraph

Article in Journal of the peripheral nervous system : JPNS, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
2.5field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 43 citations in OpenAlex.

  1. The motivation of breast cancer patients to participate in a national randomized control trial.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023
    Trial
  2. Cancer pain.Nature reviews. Disease primers · 2026
    Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Observational
  10. Frontiers in pharmacology · 2024
    Review
  11. Article
  12. Observational
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 3 countries.

Kristine BennedsgaardDanish Pain Research Center, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.ORCID 0000-0002-2686-8620
Lise VentzelDanish Pain Research Center, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Niels T AndersenBiostatistics, Department of Public Health, Aarhus University, Aarhus, Denmark.
Andreas C ThemistocleousNuffield Department of Clinical Neuroscience, University of Oxford, UK.
David L BennettNuffield Department of Clinical Neuroscience, University of Oxford, UK.
Troels S JensenDanish Pain Research Center, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Hatice TankisiDepartment of Neurophysiology, Aarhus University Hospital, Aarhus, Denmark.
Nanna B FinnerupDanish Pain Research Center, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Aarhus University · DKAarhus University Hospital · DKUniversity of Oxford · GBUniversity of the Witwatersrand · ZA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of this study was to evaluate the presence and characterization of chemotherapy-induced neuropathy (CIPN) and neuropathic pain 5 years after adjuvant chemotherapy with docetaxel or oxaliplatin. Patients from an ongoing prospective study, who had received adjuvant chemotherapy with docetaxel or oxaliplatin in 2011 to 2012 were invited to participate. The patients underwent a thorough examination with interview, neurological examination, questionnaires, assessment tools, nerve conduction studies (NCS), quantitative sensory testing, MScan motor unit number estimation (MUNE), and corneal confocal microscopy (CCM). Patients were divided into no, possible, probable, and confirmed CIPN. Out of the 132 eligible patients, 63 agreed to participate: 28 had received docetaxel and 35 had received oxaliplatin. Forty-one percent had confirmed CIPN, 34% possible or probable CIPN, and 22% did not have CIPN. The CIPN was characterized mainly by sensory nerve fiber loss, with a more pronounced large fiber than small fiber loss but also some motor fiber loss identified on NCS and MUNE. In general, patients had mild neuropathy with relatively low scores on assessment tools and no association with mood and quality of life. CCM was not useful as a diagnostic tool. Of the patients with probable or confirmed CIPN, 30% experienced pain, which was most often mild, but still interfered moderately with daily life in 20% to 25% and was associated with lower quality of life. In conclusion CIPN was confirmed in 41% 5 years after chemotherapy. The neuropathy was generally mild, but in patients with neuropathic pain it was associated with lower quality of life.

Indexed as

Severity of Illness IndexAgedAntineoplastic AgentsDiagnostic Techniques, NeurologicalDocetaxelFemaleFollow-Up StudiesHumansMaleMiddle AgedNeoplasmsNeuralgiaOxaliplatinPolyneuropathiesProspective StudiesQuality of LifeAntineoplastic AgentsDocetaxelOxaliplatinassessment toolschemotherapycorneal confocal microscopylarge fiber neuropathymotor unit number estimationnerve conduction studyneuropathic painneuropathypainsmall fiber neuropathy

Identifiers

PMID32902058
PMCPMC7756561
OpenAlexW3084998724

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.